Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼±¾Ï ȯÀÚ¿¡¼­ È£¸£¸ó¿ä¹ý ÈÄ °ñ´Ù°øÁõ ¹ß»ý¿¡ °üÇÑ ¿¬±¸ Development of Osteoporosis after Hormonal Treatment for Prostate Cancer Patient

´ëÇѺñ´¢±â°úÇÐȸÁö 1998³â 39±Ç 3È£ p.251 ~ 258
¼ººÀ¹«, À±´ö±â, °í¼º°Ç, õÁØ,
¼Ò¼Ó »ó¼¼Á¤º¸
¼ººÀ¹« (  ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç

À±´ö±â (  ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
°í¼º°Ç (  ) 
°í·Á´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
õÁØ (  ) 
°í·ÁÀÇ´ëºÎ¼Ó ¾È¾Ïº´¿ø ºñ´¢±â°ú

Abstract

¼­·Ð
¼º¼±±â´ÉÀúÇÏÁõÀº °ñ´Ù°øÁõ ¹ß»ýÀÇ Áß¿äÇÑ ¿øÀÎ ÁúȯÀ¸·Î ³²¼º¿¡¼­ ÀϾ´Â ôÃß°ñÀýÀÇ
¾à 20-30%¸¦ Â÷ÁöÇÏÁö¸¸ ³²¼º¿¡¼­´Â ÀÚ¿¬Àû ¼º¼±À§Ãà ½Ã±â°¡ ¾à 65¼¼ ÀÌÈÄ·Î ´Ê°í ¿Ü°úÀû
¼º¼±Á¦°Å¼úÀÇ ºóµµ°¡ ³·±â ¶§¹®¿¡ ¿©¼º¿¡¼­ÀÇ È°¹ßÇÑ ¿¬±¸¿¡ ºñÇØ ³²¼º °ñ´Ù°øÁõ¿¡ °üÇÑ ¿¬
±¸´Â ¸Å¿ì ºó¾àÇÏ¸ç ´õ¿íÀÌ ÀüÀÌÀü¸³¼±¾Ï Ä¡·á¸¦ À§ÇÑ ¼º¼±Á¦°Å¼ú(°íȯÀýÁ¦¼ú ȤÀº
LHRH-agonist) ÈÄ ¹ß»ýµÉ ¼ö ÀÖ´Â °ñ´Ù°ñÁõ ÇÕº´Áõ¿¡ °üÇÑ ºñ´¢±â°ú¿µ¿ª¿¡¼­ÀÇ ÃæºÐÇÑ ¿¬
±¸´Â ÀÌ·ç¾îÁ® ÀÖÁö ¾Ê´Ù.
Àü¸³¼±¾ÏÀº ¹Ì±¹À» ºñ·ÔÇÑ ¼­±¸»çȸ ¿¡¼­ °¡Àå ÈçÇÑ ³²¼ºÀÇ ¾Ç¼ºÁ¾¾çÀ¸·Î ÃÖ±Ù¿¡ ¿ì¸® ³ª
¶ó¿¡¼­µµ Æò±Õ ¼ö¸íÀÇ Áõ°¡(³ëÀμö Áõ°¡)¿Í Áø´ÜÀåºñÀÇ Çâ»ó, ¼­±¸È­µÈ ½Ä»ýÈ° µîÀ¸·Î Àü¸³
¼±¾ÏÀÇ ¹ß»ý·ü ¹× ±×·Î ÀÎÇÑ »ç¸Á·üÀÌ Áõ°¡ÇÏ°í ÀÖ°í, ÀÌ¿¡ µû¶ó ÀüÀÌÀü¸³¼±¾ÏÀÇ Ä¡·á¹ýÀ¸
·Î È£¸£¸ó¿ä¹ýÀ» »ç¿ëÇÏ¿© Ä¡·á¹Þ´Â ȯÀÚ ¼öµµ ´Ã¾î³ª°í ÀÖ¾î ÇâÈÄ ±¹³»¿¡¼­µµ Àü¸³¼±¾Ï Ä¡
·á¸¦ À§ÇÑ ³»ºÐºñ¿ä¹ý ÈÄ ¹ß»ýµÉ ¼ö ÀÖ´Â °ñ´Ù°øÁõ¿¡ ´ëÇÑ ¿¬±¸°¡ ÇÊ¿äÇÏ´Ù°í ÇÏ°Ú´Ù.
ÀúÀÚ´Â Àü¸³¼±¾Ï ȯÀÚ¿¡ ´ëÇÑ ¼º°øÀûÀΠȣ¸£¸ó Ä¡·á ÈÄ È¯ÀÚÀÇ »ýÁ¸±â°£ ¹× »îÀÇ Áú¿¡ ¿µ
ÇâÀ» ¹ÌÄ¡´Â °ñ´Ù°øÁõ ¹ß»ýÀ» ÀûÀýÇÏ°Ô ¿¹¹æ, Ä¡·áÇϱâ À§ÇÑ ±âÃÊ¿¬±¸·Î¼­ Àü¸³¼±¾Ï ȯÀÚ¿¡
¼­ ³»ºÐºñ¿ä¹ý ÈÄ ¹ß»ýÇÑ °ñ´Ù°øÁõÀÇ ºóµµ ¹× ÁøÇàÁ¤µµ¿¡ °üÇÑ ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose: Combined androgen blockade(CAB) is often used in the management of
advanced adenocarcinoma of the prostate. Recent case reports indicated that
hypogonadism from CAB therapy is associated with osteoporosis and related fracture.
The effect of CAB on bone mineral density(BMD) has not been adequately studied in
men with prostate cancer. In this study, the possibility, frequency and severity of
osteoporosis following CAB in prostate cancer patient was investigated.
Materials and Methods: A total of 19 men with advanced prostate cancer receiving
CAB were evaluated for the presence of osteoporosis defined as bone mass 2.5 standard
deviation below peak bone mass of young normal men(T-score). The BMB of the
femoral neck and lumbar spine were measured. The BMD was then compared to the
age-matched control value and reported as the Z-score. BMD measurements were
compared to duration of CAB and Gleason score.
Results: Osteoporosis occurred in 10 of 15 patients in lumbar spine, and 4 of 18
patients in femoral neck. Osteoporosis was unrelated to the type of the
CAB(orchiectomy, or LHRH-agonist). CAB caused a decrease in mean BMD of lumbar
spine and femoral neck. There is a negative linear relation between mean BMD and
duration of CAB(lumber spine; R2=0.059, Y=-2.368-0.016X, p>0.05, femoral
neck; R2=0.089, Y=-1.923-0.020x, p>0.05). There is a statistically significant
negative linear relationship between Gleason score and mean T-score of femoral
neck(lumbar spine; R2=0.391, Y=-0.08-0.371X, p>0.05, femoral neck;
R2=0.517, Y=0.855-0.450x, p<0.005).
Conclusions: Our study provide evidence for acceleration of osteoporosis among men
whose prostate cancers were treated with CAB. This study indicates a need for bone
mineral density determination at the onset of CAB and at periodic intervals there after
to begin appropriate therapy, undefined at this point, for prevention of osteoporosis and
its complications aggravated by this therapy.

Å°¿öµå

Osteoporosis; Hormonal therapy; Prostate cancer;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS